MTOR and renal cell carcinoma: In RCC cells, both inhibit RCC cell proliferation and migration by inhibiting the activation of the PI3K/AKT/mTOR pathway (Wang L. et al., 2022; Zhao et al., 2017), which suggests the spatiotemporal specificity of the PI3K/AKT pathway in metastasis.